RX 0201

Drug Profile

RX 0201

Alternative Names: Archexin; RX-0201; RX-0201 Nano; RX-0201 nanoliposomal - Rexahn Pharmaceuticals; RX-0201-N

Latest Information Update: 27 Apr 2016

Price : $50

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Renal cell carcinoma; Glioblastoma; Gastric cancer; Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer; Renal cell carcinoma
  • Preclinical Ovarian cancer

Most Recent Events

  • 20 Apr 2016 Final efficacy data from a phase Ib/IIa trial in Renal cell carcinoma presented at the American Association for Cancer Research Annual Meeting (AACR-2016)
  • 01 Feb 2016 Phase-II clinical trials in Renal cell carcinoma (Combination therapy, Metastatic disease) in USA (IV) (NCT02089334)
  • 11 Jan 2016 Interim efficacy data from a phase Ib/IIa trial in Renal cell carcinoma presented at the American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top